Skip to main content
Signal8
Launch Terminal

Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc.

NASDAQ:OLMAHealthcare
-4.50%$7.00
AH$7.12+1.71%vs close
Mkt Cap$612.48M
Float63.2M
O/S87.5M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Olema Pharmaceuticals, Inc. logoNASDAQ:OLMA$7.00-4.50%
Phase Distribution
6 lead-sponsored trials·5 active·1 completed
Phase 13
Phase 1/21
Phase 32
Status Overview
Recruiting2
Active, not recruiting3
Completed1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Active, not recruiting

    OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

    Palazestrant, Fulvestrant

    Breast Cancer, Advanced Breast Cancer +3

    Enrollment
    510
    Start
    Nov 2023
    Primary Completion
    Oct 2026est.
    Completion
    Feb 2028est.
    NCT06016738
  • Phase 3
    Recruiting

    Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    Palazestrant, Letrozole-matching placebo

    Breast Cancer, Locally Advanced Breast Cancer +3

    Enrollment
    1,000
    Start
    Nov 2025
    Primary Completion
    Dec 2028est.
    Completion
    Jan 2032est.
    NCT07085767
  • Phase 1/2
    Completed

    A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

    OP-1250

    Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer

    Enrollment
    153
    Start
    Aug 2020
    Primary Completion
    Jul 2024
    Completion
    Jul 2024
    NCT04505826
  • Phase 1
    Active, not recruiting

    A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

    Palazestrant, Palbociclib

    Breast Cancer

    Enrollment
    60
    Start
    Dec 2021
    Primary Completion
    Mar 2026est.
    Completion
    Mar 2026est.
    NCT05266105
  • Phase 1
    Active, not recruiting

    Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

    Palazestrant, Ribociclib

    Metastatic Breast Cancer, ER-positive Breast Cancer +3

    Enrollment
    190
    Start
    Aug 2022
    Primary Completion
    Dec 2027est.
    Completion
    Jan 2028est.
    NCT05508906
  • Phase 1
    Recruiting

    Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    OP-3136, Fulvestrant

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) +4

    Enrollment
    180
    Start
    Dec 2024
    Primary Completion
    May 2027est.
    Completion
    Aug 2027est.
    NCT06784193
Search ClinicalTrials.gov for “Olema Pharmaceuticals”